Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

B of A Securities Upgrades Cellebrite DI to Buy, Announces $12 Price Target

Author: Benzinga Newsdesk | February 16, 2024 08:34am
B of A Securities analyst Tomer Zilberman upgrades Cellebrite DI (NASDAQ:CLBT) from Neutral to Buy and announces $12 price target.

Posted In: CLBT